» Articles » PMID: 34386349

A Proline Metabolism Selection System and Its Application to the Engineering of Lipid Biosynthesis in Chinese Hamster Ovary Cells

Overview
Specialty Biochemistry
Date 2021 Aug 13
PMID 34386349
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Chinese hamster ovary (CHO) cells are the leading mammalian cell host employed to produce complex secreted recombinant biotherapeutics such as monoclonal antibodies (mAbs). Metabolic selection marker technologies (e.g. glutamine synthetase (GS) or dihydrofolate reductase (DHFR)) are routinely employed to generate such recombinant mammalian cell lines. Here we describe the development of a selection marker system based on the metabolic requirement of CHO cells to produce proline, and that uses pyrroline-5-carboxylase synthetase (P5CS) to complement this auxotrophy. Firstly, we showed the system can be used to generate cells that have growth kinetics in proline-free medium similar to those of the parent CHO cell line, CHOK1SV GS-KO™ grown in proline-containing medium. As we have previously described how engineering lipid metabolism can be harnessed to enhance recombinant protein productivity in CHO cells, we then used the P5CS selection system to re-engineer lipid metabolism by over-expression of either sterol regulatory element binding protein 1 (SREBF1) or stearoyl CoA desaturase 1 (SCD1). The cells with re-engineered proline and lipid metabolism showed consistent growth and P5CS, SCD1 and SREBF1 expression across 100 cell generations. Finally, we show that the P5CS and GS selection systems can be used together. A GS vector containing the light and heavy chains for a mAb was super-transfected into a CHOK1SV GS-KO™ host over-expressing SCD1 from a P5CS vector. The resulting stable transfectant pools achieved a higher concentration at harvest for a model difficult to express mAb than the CHOK1SV GS-KO™ host. This demonstrates that the P5CS and GS selection systems can be used concomitantly to enable CHO cell line genetic engineering and recombinant protein expression.

Citing Articles

CHO stable pool fed-batch process development of SARS-CoV-2 spike protein production: Impact of aeration conditions and feeding strategies.

Reyes S, Pham P, Durocher Y, Henry O Biotechnol Prog. 2024; 41(1):e3507.

PMID: 39329353 PMC: 11831418. DOI: 10.1002/btpr.3507.


SiMPl-GS: Advancing Cell Line Development via Synthetic Selection Marker for Next-Generation Biopharmaceutical Production.

Yoon C, Lee E, Kim D, Joung S, Kim Y, Jung H Adv Sci (Weinh). 2024; 11(38):e2405593.

PMID: 39105414 PMC: 11481413. DOI: 10.1002/advs.202405593.


Context-dependent genomic locus effects on antibody production in recombinant Chinese hamster ovary cells generated through random integration.

Woo H, Kim J, Kim S, Kim D, Moon J, Park D Comput Struct Biotechnol J. 2024; 23:1654-1665.

PMID: 38680870 PMC: 11046053. DOI: 10.1016/j.csbj.2024.04.023.


Building blocks needed for mechanistic modeling of bioprocesses: A critical review based on protein production by CHO cells.

Gonzalez-Hernandez Y, Perre P Metab Eng Commun. 2024; 18:e00232.

PMID: 38501051 PMC: 10945193. DOI: 10.1016/j.mec.2024.e00232.


Recombinant therapeutic proteins degradation and overcoming strategies in CHO cells.

Geng S, Zhao X, Zhang X, Zhang J, Mi C, Wang T Appl Microbiol Biotechnol. 2024; 108(1):182.

PMID: 38285115 PMC: 10824870. DOI: 10.1007/s00253-024-13008-6.


References
1.
Budge J, Knight T, Povey J, Roobol J, Brown I, Singh G . Data for engineering lipid metabolism of Chinese hamster ovary (CHO) cells for enhanced recombinant protein production. Data Brief. 2020; 29:105217. PMC: 7013132. DOI: 10.1016/j.dib.2020.105217. View

2.
van Herpen N, Schrauwen-Hinderling V . Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol Behav. 2008; 94(2):231-41. DOI: 10.1016/j.physbeh.2007.11.049. View

3.
Roobol A, Roobol J, Carden M, Smith M, Hershey J, Bastide A . The chaperonin CCT interacts with and mediates the correct folding and activity of three subunits of translation initiation factor eIF3: b, i and h. Biochem J. 2013; 458(2):213-24. DOI: 10.1042/BJ20130979. View

4.
Bebbington C, Renner G, Thomson S, King D, Abrams D, Yarranton G . High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (N Y). 1992; 10(2):169-75. DOI: 10.1038/nbt0292-169. View

5.
Povey J, OMalley C, Root T, Martin E, Montague G, Feary M . Rapid high-throughput characterisation, classification and selection of recombinant mammalian cell line phenotypes using intact cell MALDI-ToF mass spectrometry fingerprinting and PLS-DA modelling. J Biotechnol. 2014; 184:84-93. DOI: 10.1016/j.jbiotec.2014.04.028. View